Alnylam Pharmaceuticals
ALNY
#632
Rank
C$53.68 B
Marketcap
C$402.35
Share price
-4.32%
Change (1 day)
12.22%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): C$2.48

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$2.45. In 2023 the company made an earnings per share (EPS) of C-$4.80 an increase over its 2022 EPS that were of C-$12.62.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$2.48
2023C-$4.80-62%
2022C-$12.6229.03%
2021C-$9.78-3.36%
2020C-$10.12-8.48%
2019C-$11.067.67%
2018C-$10.2739.74%
2017C-$7.3512.94%
2016C-$6.5138.84%
2015C-$4.69-32.88%
2014C-$6.98259.44%
2013C-$1.94-31.25%
2012C-$2.83

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.78 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$2.81 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$58.59 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.72-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$0.99-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.33-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.68-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.48-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA